Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCs Adjusting cost structure to fund operations into late 2022 HOPKINTON, Mass. , Jan. 29, 2020 (GLOBE…
Read more